Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04843878 · ClinicalTrials.gov registry record
COVID-19 Testing Pilot Study
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 326
- Enrollment target
NCT04843878: Completed study, sponsored by University of Pennsylvania.
NCT04843878 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 326 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04843878 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the reliability of a low-cost rapid diagnostic test for COVID-19. The method of the testing procedure uses electrochemistry to detect COVID-19 spike proteins within human samples. To test the effectiveness of this new method, patients will be recruited as they present for testing at ambulatory Penn testing sites. Patients will be asked to self-collect one anterior nares samples under the supervision of authorized study personnel.
Primary Outcome
The accuracy of the new prototype testing method will be determined by comparing the prototype's result to the clinical gold standard PCR test. The accuracy will be determined by calculating the percentage of the test's ability to correctly identify both the presence and absence of virus compared to the PCR result for the positive and negative results.
Interventions
- DIAGNOSTIC_TEST COVID Detect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2021-03-12 |
What the finished NCT04843878 record still lists
NCT04843878 is an observational study that tracks outcomes without assigning an intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which COVID Detect is the first listed.
NCT04843878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04843878 about?
NCT04843878 is a clinical study titled "COVID-19 Testing Pilot Study". The purpose of this study is to determine the reliability of a low-cost rapid diagnostic test for COVID-19. The method of the testing procedure uses electrochemistry to detect COVID-19 spike proteins within human samples. To test the effectiveness of this new method, patients will be recruited as th...
What is the current status of trial NCT04843878?
This trial is currently completed. The enrollment target is 326 participants. The study started on 2021-01-05. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT04843878?
The interventions under investigation include: COVID Detect (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04843878?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI